(Dana-Farber Cancer Institute) A combination of two drugs — one of them an immunotherapy agent — could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Original source: https://www.eurekalert.org/pub_releases/2019-02/dci-dcm021419.php